Tuesday, 28 July 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 28 July 2026
News

Company in strife with UK watchdog

 Posted 28 July 2026 PM

The UK marketing watchdog has reprimanded Sanofi and warned it may face further sanctions for “very serious breaches” of its code of practice, related to disparaging claims made about Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo and the UK’s immunisation program.

The Prescription Medicines Code of Practice Authority (PMCPA) issued its rulings this month on two cases that it had investigated following complaints by Pfizer in August 2025. The first case covered articles in the Sunday Express newspaper and Health Service Journal (HSJ) and two social media posts made by Sanofi employees.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (20)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.